Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

MORF-057 is under clinical development by Eli Lilly and Co and currently in Phase II for Crohn's Disease (Regional Enteritis).

BCD-245 is under development for treatment of neuroblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and soft tissue sarcoma. It acts by targeting GD2 and is administered through intravenous ...

Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Liver Cancer. According to GlobalData, Phase I drugs for Liver Cancer have a 78% phase transition success rate ...

TeLE is under clinical development by Bodor Laboratories and currently in Phase I for Unspecified Dermatological Disorders.

Pociredir is under clinical development by Fulcrum Therapeutics and currently in Phase I for Sickle Cell Disease.

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

CT-7439 is under development for the treatment of solid tumors including breast cancer, ovarian cancer and Ewing's Sarcoma. It acts by targeting cyclin dependent kinase 12 and 13 (CDK12 and 13). It is ...

TAS-0728 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Endometrial Cancer.

Human Amniotic Epithelial Stem Cells is under clinical development by iCELL Biotechnology and currently in Phase I for Parkinson's Disease.

Gen1E-1124 is under clinical development by GEn1E Lifesciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.